- Home
- GIGM vs SIGA Comparison
GIGM vs SIGA Comparison
Compare GIGM & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | SIGA |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 462.6M |
| IPO Year | 2000 | 1997 |
Fundamental Metrics
Financial Performance| Metric | GIGM | SIGA |
|---|---|---|
| Price | $1.53 | $6.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.9K | ★ 341.6K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.51% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | $3,397,000.00 | ★ $172,249,641.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | ★ N/A | $6.13 |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $4.95 |
| 52 Week High | $1.89 | $9.62 |
Technical Indicators
Market Signals| Indicator | GIGM | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 43.82 |
| Support Level | $1.50 | $6.22 |
| Resistance Level | $1.56 | $6.45 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 31.33 | 56.59 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.